Asian Journal of Pharmaceutical and Biological Research (AJPBR)
Published by Young Pharmaceutical and Biological Scientist Group, country India, Quaterly journal
Current impact factor: 0.00
Impact Factor Rankings
|Website||Pharmaceutical sciences, Biological Sciences, Medical sciences|
|Material type||Orignial articles, review articles, Short communication, on Pharmacy sciences, Biological Sciecnes Medicine Sciences|
Publications in this journal
- [Show abstract] [Hide abstract]
ABSTRACT: Objective: The present study was designed to evaluate some hormonal impact on menstrual cycle pattern of HIV infected women of child bearing age and to assess whether the changes observed are directly related to HIV infections. Methods: This was a prospective study that involved 214 female participants aged between 15 and 45 years conducted at Nnamdi Azikiwe University Teaching Hospital Nnewi. Based on the result of the screening, they were grouped as: HIV seropositive subjects (n=79), HIV seropositive subjects on Anti Retroviral Therapy (ART) (n=80) and control HIV seronegative subjects (n=55). After due consent, a detailed medical history was obtained using questionnaire. Blood samples collected from the participants were used for double HIV seroreactivity by rapid immunoassay and immunochromatographic techniques and hormonal assay using immunoenzymometric method. Results: Menstrual abnormalities were reported in 76% of women in the study group. Secondary amenorrhea was observed in 32(40.5%) of HIV subjects, 20(25%) of HIV subjects on ART when compared with 1(1.8%) in control subjects. Hypomenorrhea was observed in 16(20.3%) of HIV subjects, when compared with 1(1.8%) observed in control subjects. Hypermenorrhea was observed in 18(22.5%) of HIV subjects on ART when compared with the 1(1.8%) in control subjects. The mean (±SD) serum FSH ( IU/ml) and LH ( IU/ml) were significantly higher at follicular and luteal HIV subjects whether on ART or not when compared with their corresponding control subjects (P<0.05 respectively). The mean (±SD) serum Prolactin (ng/ml) at follicular HIV subjects was significantly higher when compared with the follicular control subjects (P<0.05). Similar observation was made in luteal HIV subjects when compared with the counterparts on ART (P<0.05). Conclusion: the study suggests a marked hormonal impact on the menstrual cycle pattern observed in the study subjects which may be attributed to HIV infections and ART as well. Key Words: Menstrual Pattern, Irregularities, HIV, Hormones
- [Show abstract] [Hide abstract]
ABSTRACT: ABSTRACT: Measles is the most deadly of all childhood rash/fever illnesses. The disease spreads very easily, so it is important to be protected against infection. Extensive vaccination is the best way to prevent measles. We conducted a descriptive study conducted in 5 health service centers of Bandar Abbas and 194 vaccinated children from May 2012 to December 2012. Target groups were children with 13 to 18 months age who received first MMR vaccine (Group A) and 19 to 24 month's age children who received first and second MMR vaccine (Group B). We evaluated the anti-measles anti-body ELIZA method in both groups 1 to 6 months after vaccination. The results of this study showed that 1 to 6 month after first and second MMR vaccination, highly effective immunity against measles (98.96%) is acquired In 137 children (male, female) of group A, mean titer of anti-measles antibody was 57.69 IU/ml and in 58 children (male, female) in group B, was 55.70. Anti-measles antibody under 1.2 IU/ml considered as seronegative. Only two children in group A had insufficient immunity against measles. We found no significant difference between serum level of anti-measles antibody in two groups of children and also no remarkable correlation between gender and serum level of anti-measles anti-body found.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.